SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Idenix Pharmaceuticals (IDIX)
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
412 15 0 IDIX
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
112Week of 1/19: 55 Trx, 38 Nrx. 1.9% and 0.8% share. rkrw-1/29/2007
111Merrill: Initiating/Reinstating Coverage Idenix Pharmaceuticals Inc (IDIX, US$9tom pope-1/17/2007
110Tyzeka rx week of 1/5: New rx 22, Total 34. 1.1% nrx share. Seem to be averagingrkrw-1/15/2007
109‘go seek’ has updated the IDIX <i>ReadMeFirst</i>: investorshub.coDewDiligence_on_SI-1/15/2007
108JPM webcast notes: Message 23168308DewDiligence_on_SI-1/9/2007
107Will nvs break out such a small product? My guess would be closer to $2.5M mayrkrw-12/19/2006
106We’ll have the actual Tyzeka/Sebivo sales at 1:15 am ET on January 18 (when NVS DewDiligence_on_SI-12/19/2006
105Bought back in today. I agree that VX-950 is looking merely good -- as opposed tuck-12/19/2006
104Valeant Pharmaceuticals and Metabasis Therapeutics License Rights to Hepatitis Bdr.praveen-12/13/2006
103IDIX fills open slot on BoD: investorshub.comDewDiligence_on_SI-12/7/2006
102Barron’s questions valuation disparity between VRTX and IDIX: investorshub.comDewDiligence_on_SI-11/25/2006
101I was just being silly, making a not so funny reference to a failed drug from Phtuck-11/9/2006
100I'm not seeing the comparison. Different compounds and different indicationsrkrw-11/8/2006
99Hopefully, it'll do better than Reverset, it's apparently gotten much fatuck-11/8/2006
98Here's a program to root for despite any vested interests. Potentially disrurkrw-11/8/2006
97DeletedRobohogs-11/5/2006
96Interesting details in the prospectus on the idix/licensor arrangement. Certainlrkrw-11/4/2006
95Pricing out, big 30% discount to baraclude.rkrw-10/30/2006
94New graphics on Tyzeka vs Hepsera efficacy and U.S. HBV market share: investorDewDiligence_on_SI-10/28/2006
93Links to IDIX webcast and slides: Webcast: ir.idenix.com Slides: library.corpDewDiligence_on_SI-10/27/2006
92IDIX pre-AASLD and 3Q06 CC notes: investorshub.comDewDiligence_on_SI-10/27/2006
91Tyzeka FDA label: fda.govDewDiligence_on_SI-10/26/2006
90This was a smart and low cost, low risk move for idix. mbrx platform I find veryrkrw-10/26/2006
89There's conservative and there's conservative. Your cost numbers make norkrw-10/25/2006
88I'm being conservative.DewDiligence_on_SI-10/25/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News